Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion.

BACKGROUND AIMS Pooled human platelet lysate (HPL) is becoming the new gold standard as supplement for ex vivo cell culture for clinical protocols. However, the risk of pathogen contamination of HPL increases with the platelet pool size. We hypothesized that hollow fiber anion exchange membrane chromatography using QyuSpeed D (QSD) could remove resistant and untested bloodborne pathogens, such as parvoviruses and prions, from HPL-supplemented growth media without substantially affecting their capacity to support ex vivo cell expansion. METHODS Frozen or thawed platelet concentrates were serum-converted and centrifuged for obtaining HPL that was added to various growth media (ca. 100 mL), filtered through a 0.6-mL QSD membrane and characterized for proteins, growth factors and chemical composition. Capacity to expand Chinese hamster ovary, periodontal ligament, gingival fibroblast cells and Wharton's jelly mesenchymal stromal cells was studied. Removal of porcine parvovirus (PPV) and of the 263K prion strain of hamster-adapted scrapie was studied by spiking experiments following international guidelines. RESULTS QSD had minimal impact on HPL-supplemented medium composition in proteins, growth factors and chemical content, nor capacity to expand and differentiate cells. In addition, QSD could remove ≥5.58 log10 [TCID50/mL] and ≥3.72 log10 of PPV and the 263K prion, respectively. CONCLUSIONS QSD hollow fiber chromatography can be used to improve the virus and prion safety of HPL-supplemented media to safely expand cells for clinical protocols. These data bring new perspectives for increasingly safer use of pooled HPL in cell therapy and regenerative medicine applications.

[1]  R. Rubenstein,et al.  A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins , 2001, Transfusion.

[2]  Wolfgang Wagner,et al.  Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. , 2014, Cytotherapy.

[3]  G. Gstraunthaler,et al.  A plea to reduce or replace fetal bovine serum in cell culture media , 2013, Cytotechnology.

[4]  D. Strunk,et al.  Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. , 2009, Journal of visualized experiments : JoVE.

[5]  G. Gstraunthaler,et al.  Human Platelet Lysates Successfully Replace Fetal Bovine Serum in Adipose-Derived Adult Stem Cell Culture , 2014 .

[6]  Walter Pfaller,et al.  Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. , 2011, ALTEX.

[7]  J. Kang,et al.  Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non‐leucoreduced platelet‐rich plasma‐derived platelets suspended in plasma , 2014, Vox sanguinis.

[8]  B. Griffin,et al.  Studies on the Removal of Abnormal Prion Protein by Processes Used in the Manufacture of Human Plasma Products , 2000, Vox sanguinis.

[9]  R. Somerville,et al.  Studies on the removal of a bovine spongiform encephalopathy‐derived agent by processes used in the manufacture of human immunoglobulin , 2002, Vox sanguinis.

[10]  T. Burnouf,et al.  A chromatographically purified human TGF‐β1 fraction from virally inactivated platelet lysates , 2011, Vox sanguinis.

[11]  L. Labanca,et al.  Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions , 2014, Cytotherapy.

[12]  M E Bolander,et al.  Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur , 1990, The Journal of cell biology.

[13]  L. Otero,et al.  Cell therapy with bone marrow stromal cells after intracerebral hemorrhage: impact of platelet-rich plasma scaffolds. , 2013, Cytotherapy.

[14]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[15]  D. Strunk,et al.  Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow , 2009, Stem cells.

[16]  Yu-Wen Wu,et al.  Antimicrobial activity of platelet (PLT)‐poor plasma, PLT‐rich plasma, PLT gel, and solvent/detergent‐treated PLT lysate biomaterials against wound bacteria , 2013, Transfusion.

[17]  G Gstraunthaler,et al.  Optimization of chemically defined cell culture media--replacing fetal bovine serum in mammalian in vitro methods. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[18]  T. Burnouf,et al.  Human blood-derived fibrin releasates: composition and use for the culture of cell lines and human primary cells. , 2012, Biologicals : journal of the International Association of Biological Standardization.

[19]  H. Klüter,et al.  Human AB Serum and Thrombin‐Activated Platelet‐Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue , 2007, Stem cells.

[20]  G. D. Hunter,et al.  An experimental examination of the scrapie agent in cell membrane mixtures. II. The association of scrapie activity with membrane fractions. , 1971, Journal of comparative pathology.

[21]  W. Holnthoner,et al.  Human platelet lysate is a feasible candidate to replace fetal calf serum as medium supplement for blood vascular and lymphatic endothelial cells. , 2014, Cytotherapy.

[22]  T. Burnouf,et al.  Quantitative assessment of the kinetics of growth factors release from platelet gel , 2008, Transfusion.

[23]  R. Benjamin,et al.  The safety of the blood supply--time to raise the bar. , 2015, The New England journal of medicine.

[24]  T. Burnouf.  Modern Plasma Fractionation , 2007, Transfusion Medicine Reviews.

[25]  J. Reems,et al.  Serum-converted platelet lysate can substitute for fetal bovine serum in human mesenchymal stromal cell cultures. , 2013, Cytotherapy.

[26]  T Burnouf,et al.  Reducing the risk of infection from plasma products: specific preventative strategies. , 2000, Blood reviews.

[27]  P. Horn,et al.  Platelet lysates and their role in cell therapy , 2014 .

[28]  Thierry Burnouf,et al.  Expansion of adipose tissue mesenchymal stromal progenitors in serum‐free medium supplemented with virally inactivated allogeneic human platelet lysate , 2011, Transfusion.

[29]  T. Burnouf,et al.  Removal of Transmissible Spongiform Encephalopathy Prion from Large Volumes of Cell Culture Media Supplemented with Fetal Bovine Serum by Using Hollow Fiber Anion-Exchange Membrane Chromatography , 2015, PloS one.

[30]  T. Burnouf,et al.  Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion , 2014, New Biotechnology.

[31]  L. McShane,et al.  Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt‐Jakob disease in humans , 1999, Transfusion.

[32]  Faming Chen,et al.  The effects of human platelet lysate on dental pulp stem cells derived from impacted human third molars. , 2012, Biomaterials.

[33]  Dirk Strunk,et al.  Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? , 2016, Biomaterials.

[34]  Carmen Koch,et al.  Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. , 2010, Cytotherapy.

[35]  J. Feijen,et al.  The effect of platelet lysate supplementation of a dextran-based hydrogel on cartilage formation. , 2012, Biomaterials.

[36]  A. Ignatius,et al.  Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components , 2012, Cytotherapy.

[37]  T. Burnouf,et al.  Current strategies to prevent transmission of prions by human plasma derivatives. , 2006, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[38]  P. Brown,et al.  The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy , 1998, Transfusion.

[39]  J. Miller,et al.  Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. , 2000, Journal of virological methods.

[40]  M. Lindberg,et al.  Adipose Tissue , 2018 .

[41]  D. Kaplan,et al.  Characteristics of platelet gels combined with silk. , 2014, Biomaterials.

[42]  J. Taylor,et al.  Epidermal growth factor. Physical and chemical properties. , 1972, The Journal of biological chemistry.

[43]  P. Brown.  Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy , 2005, Vox sanguinis.

[44]  Gerhard Gstraunthaler,et al.  Alternatives to the use of fetal bovine serum: serum-free cell culture. , 2003, ALTEX.

[45]  J. Römisch,et al.  Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)‐treated plasma OctaplasLG® , 2009, Vox sanguinis.

[46]  Sara M. Oliveira,et al.  Layer-by-layer assembled cell instructive nanocoatings containing platelet lysate. , 2015, Biomaterials.

[47]  J. Taylor‐Papadimitriou,et al.  Transforming growth factor-β1 is constitutively secreted by Chinese hamster ovary cells and is functional in human cells. , 2011, Biotechnology and bioengineering.

[48]  S. Cohen,et al.  Epidermal growth factor , 1972, The Journal of investigative dermatology.